Cell News and Research

RSS

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.

10 Mar 2010

Insulin resistance in Hepatitis C patients: Mostly in muscle and not in liver

We have known for several years that Hepatitis C, a common cause of liver cirrhosis and cancer, also makes people three to four times more likely to develop Type 2 diabetes.

10 Mar 2010

Papaya's anticancer effect against broad range of lab-grown tumors documented

The humble papaya is gaining credibility in Western medicine for anticancer powers that folk cultures have recognized for generations.

10 Mar 2010

Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program

Diamyd Medical announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company’s lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA.

10 Mar 2010

Skin transplant surgery safe and effective for treating vitiligo

In the first study of its kind in the United States, Henry Ford Hospital showed that skin transplant surgery is safe and effective for treating vitiligo.

10 Mar 2010

Lonza acquires access to PCA technology patent portfolio

Odyssey Thera, Inc., announced today the signing of an agreement with Lonza to make Odyssey Thera's proprietary Protein-fragment Complementation Assay (PCA) technology, as part of compound profiling services, available to life science and drug discovery researchers.

10 Mar 2010

ZenBio to be commercial source for popular murine 3T3-L1 cell line

ZenBio announce that they will be a commercial source for the popular murine 3T3-L1 cell line, which has been fundamental in metabolic disease research for 30 years.

10 Mar 2010

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

2-day International Scientific Symposium features technological advances in stem cell research

As the finale of the ESTOOLS project, the consortium partners are holding a major 2-day International Scientific Symposium, and the final Ethics Workshop.

10 Mar 2010

Genetic variant increases risk of lung cancer for light and heavy smokers, say researchers

Individuals with a certain type of genetic susceptibility to lung cancer face a greatly increased risk for the deadly disease with even a small exposure to cigarette smoke, a study team that includes researchers from the University of Cincinnati has concluded.

10 Mar 2010

Researchers identify a new mechanism for tumor control

The interaction of a ligand (Neurotrophine-3) and its dependence receptor (TrkC) constitutes a novel mechanism for tumor control in pediatric cancers such as neuroblastoma, and may also be important to the inhibition of other cancers such as breast cancer.

9 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

ETEX receives FDA marketing clearance for CarriGen Porous Bone Substitute Material

ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.

9 Mar 2010

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.

9 Mar 2010

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Omeros Corporation today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders.

9 Mar 2010

"Cyberbullying" leads to depression in LGBT youth

Schools are typically on guard against students who bully by inflicting repeated violence on other students. But technology has given rise to a relatively new form of bullying which inflicts emotional harm in a stealth manner, working through Web sites, chat rooms, e-mail, cell phones and instant messaging.

9 Mar 2010

USF study: HHV-6 causes permanent infection by inserting its DNA into human chromosomes

Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life. Now, a team led by Peter Medveczky, MD, a professor in the Department of Molecular Medicine at the University of South Florida, has discovered that in some individuals, HHV-6 causes such a permanent infection by inserting or "integrating" its DNA into human chromosomes.

9 Mar 2010

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.

9 Mar 2010

Study shows NK cells use bungee-like nanotube to destroy dangerous cells

Immune cells ensnare dangerous cells that are on the run with a bungee-like nanotube, according to research published today in the Proceedings of the National Academy of Sciences. The study, by researchers from Imperial College London, shows that natural killer (NK) cells use this bungee to destroy cells that could otherwise escape them.

9 Mar 2010

QoLT Center receives $1.5M NSF Innovation Award

An already promising initiative to assist start-up firms that commercialize technologies associated with the Quality of Life Technology (QoLT) Center is now expanding thanks to a three-year, $1.5 million Innovation Award from the National Science Foundation's (NSF) Division of Engineering Education and Centers.

9 Mar 2010

Cell News and Research

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

Insulin resistance in Hepatitis C patients: Mostly in muscle and not in liver

Papaya's anticancer effect against broad range of lab-grown tumors documented

Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program

Skin transplant surgery safe and effective for treating vitiligo

Lonza acquires access to PCA technology patent portfolio

ZenBio to be commercial source for popular murine 3T3-L1 cell line

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

2-day International Scientific Symposium features technological advances in stem cell research

Genetic variant increases risk of lung cancer for light and heavy smokers, say researchers

Researchers identify a new mechanism for tumor control

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

ETEX receives FDA marketing clearance for CarriGen Porous Bone Substitute Material

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

"Cyberbullying" leads to depression in LGBT youth

USF study: HHV-6 causes permanent infection by inserting its DNA into human chromosomes

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Study shows NK cells use bungee-like nanotube to destroy dangerous cells

QoLT Center receives $1.5M NSF Innovation Award

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News